AptaBio Therapeutics Inc (293780) - Total Liabilities

Latest as of September 2025: ₩22.51 Billion KRW ≈ $15.25 Million USD

Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has total liabilities worth ₩22.51 Billion KRW (≈ $15.25 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of AptaBio Therapeutics Inc to evaluate the company's liquid asset resilience ratio.

AptaBio Therapeutics Inc - Total Liabilities Trend (2017–2024)

This chart illustrates how AptaBio Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AptaBio Therapeutics Inc asset portfolio.

AptaBio Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of AptaBio Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Caisse Regionale de Credit Agricole Mutuel Loire HauteLoire PA:CRLO	France	€12.54 Billion
Maiden Holdings Ltd NASDAQ:MHLD	USA	$1.20 Billion
CF Acquisition VII Corp NASDAQ:CFFS	USA	$12.74 Million
Hanyang Digitech Co. Ltd KQ:078350	Korea	₩175.58 Billion
Eusu Holdings KO:000700	Korea	₩84.65 Billion
CONDOR ENERGIES INC. F:WQ6	Germany	€76.61 Million
ReaLy Development & Construction TWO:2596	Taiwan	NT$3.78 Billion
Gandhi Special Tubes Limited NSE:GANDHITUBE	India	Rs241.06 Million

Liability Composition Analysis (2017–2024)

This chart breaks down AptaBio Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of AptaBio Therapeutics Inc to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.27	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AptaBio Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AptaBio Therapeutics Inc (2017–2024)

The table below shows the annual total liabilities of AptaBio Therapeutics Inc from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩23.24 Billion ≈ $15.75 Million	-25.42%
2023-12-31	₩31.16 Billion ≈ $21.11 Million	+732.10%
2022-12-31	₩3.74 Billion ≈ $2.54 Million	+15.36%
2021-12-31	₩3.25 Billion ≈ $2.20 Million	-4.64%
2020-12-31	₩3.40 Billion ≈ $2.31 Million	+51.33%
2019-12-31	₩2.25 Billion ≈ $1.52 Million	+11.52%
2018-12-31	₩2.02 Billion ≈ $1.37 Million	-95.26%
2017-12-31	₩42.54 Billion ≈ $28.83 Million	--

About AptaBio Therapeutics Inc

KQ:293780 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$114.59 Million

₩169.08 Billion KRW

Market Cap Rank

#18757 Global

#871 in Korea

Share Price

₩6290.00

Change (1 day)

-1.72%

52-Week Range

₩4000.00 - ₩10420.00

All Time High

₩61500.00